Vaxil Bio

Vaxil Bio Gross Margin

Gross Margin of Vaxil Bio (VXL.V) as of Oct 18, 2026.

Gross Margin

-

Last updated:

Gross Margin of Vaxil Bio is 2026 - . Gross Margin of Vaxil Bio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaxil Bio Stock analysis

What does Vaxil Bio do? Vaxil Bio Ltd is a biotechnology company based in Toronto, Canada, specializing in immunotherapy for cancer and infectious diseases. Listed on March 2, 2011, the firm develops novel treatments using a platform based on signal peptides. Its advanced product, ImMucin, is a vaccine derived from MUC1 signal peptides that completed Phase I/II trials for multiple myeloma. The company also holds candidates for COVID-19 and tuberculosis vaccines, as well as monoclonal antibodies for oncology and infectious diseases. Additionally, Vaxil Bio has initiated a pre-clinical program for a drug delivery polymer targeting E-selectin, licensed from BGN Technologies, aiming to create targeted therapies against critical disease targets. Vaxil Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaxil Bio stock

On Eulerpool you can find the complete historical development of Gross Margin Vaxil Bio since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Vaxil Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Vaxil Bio

All Key Metrics — Vaxil Bio